Medtronic (MDT) said Monday its deep brain stimulation system for the treatment of Parkinson's disease symptoms has been approved by the Food and Drug Administration.

The company's BrainSense adaptive deep brain stimulation provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation. It uses a surgically implanted neurostimulator to transmit electrical signals to specific parts of the brain affected by neurological disorders.

The approval also includes Medtronic's BrainSense electrode identifier, which helps reduce patient time spent in clinic to program their deep brain stimulation settings. By using EI, clinicians can conduct an accurate and precise initial programming, 85% faster compared to traditional electrode selection, the company said.